The present invention addresses the problem of providing a compound which has few adverse side effects, high safety and an antagonistic activity to a µ opioid receptor. A compound represented by general formula (I) [wherein R1 and R2 may be the same as or different from each other and independently represent a hydrogen atom or a halogen atom (wherein a case in which each of R1 and R2 represents a halogen atom is excluded)； R3 represents a C1-C3 alkyl group or a vinyl group； and R4 represents formula (II) (wherein R5 represents a hydroxy group or a C1-C3 alkoxy group； and R6 and R7 may be the same as or different from each other and independently represent a hydrogen atom or a halogen atom) or formula (III) (wherein the ring A represents a C5-C7 cycloalkyl group which may be substituted by a C1-C3 alkoxy group and is substituted by a halogen atom or a 5- to 7-membered saturated heterocyclic group which is substituted by a halogen atom)] or a pharmacologically acceptable salt thereof.
